Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKMYT1 | Q99640 | 1/20 | 0.52 |
| ▸ | SYK | P43405 | 3/20 | 0.47 |
| ▸ | CDK2 | P24941 | 3/20 | 0.46 |
| ▸ | CDK9 | P50750 | 3/20 | 0.46 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.46 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.46 |
| ▸ | NEK2 | P51955 | 1/20 | 0.44 |
| ▸ | GAK | O14976 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 5/20 | 0.42 |
| ▸ | JAK2 | O60674 | 5/20 | 0.42 |
| ▸ | JAK1 | P23458 | 3/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | ITK | Q08881 | 1/20 | 0.41 |
| ▸ | JAK3 | P52333 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4818238 | 0.88 | MAP4K1 (0.45) | PKMYT1SYKCDK2KDRJAK2 | |
| SCHEMBL588382 | 0.84 | PKMYT1 (0.49) | PKMYT1SYKCDK2CDK9CCNT1 | |
| SCHEMBL589236 | 0.81 | PKMYT1 (0.47) | PKMYT1CDK2CDK9CCNT1CCNE1 | |
| SCHEMBL588644 | 0.81 | PKMYT1 (0.47) | PKMYT1CDK2CDK9CCNT1CCNE1 | |
| SCHEMBL4811690 | 0.79 | PKMYT1 (0.67) | PKMYT1SYKCDK2NEK2KDR | |
| SCHEMBL10187811 | 0.74 | SYK (0.59) | SYKCDK2CDK9CCNT1CCNE1 | |
| SCHEMBL6624292 | 0.74 | GHSR (0.39) | EGFR | |
| SCHEMBL30515513 | 0.73 | MAP3K5 (0.59) | PKMYT1CDK2CDK9CCNT1CCNE1 | |
| SCHEMBL15939450 | 0.73 | KDR (0.55) | PKMYT1CDK2CDK9CCNT1CCNE1 | |
| SCHEMBL13980535 | 0.71 | KDR (0.76) | KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7459455-B2 | Pyrimidine compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-02 | — | — | US | disclosed |
| US-20050085637-A1 | Antiproliferative agents; angiogenesis inhibitors | SMITHKLINE BEECHAM CORPORATION | 2005-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085637-A1 | Antiproliferative agents; angiogenesis inhibitors | TIE1, TEK, KDR | PKMYT1 2374/4885SYK 1832/4885CDK2 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.